Novo Nordisk
Novo Nordisk's affiliate in Algeria
Last updated October 17, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Novo Nordisk A/S is a Danish multinational healthcare and pharmaceutical company headquartered in Bagsværd, Denmark. The company develops, manufactures, and markets medicines and delivery systems for diabetes, obesity, cardiovascular disease, rare blood disorders, growth disorders, and selected other chronic conditions. Its modern identity is closely associated with insulin, injectable and oral glucagon-like peptide-1 therapies, and a long-standing emphasis on protein-based medicines and patient-oriented delivery devices. The company traces its origins to the Danish insulin industry of the 1920s. In 1923, physiologist August Krogh and his wife Marie Krogh returned from North America with permission to produce insulin in Denmark. Working with physician Hans Christian Hagedorn and industrialist August Kongsted, they established the activities that became Nordisk Insulinlaboratorium. In 1925, former Nordisk employees Harald and Thorvald Pedersen founded Novo Terapeutisk Laboratorium. The two businesses competed for decades before merging in 1989 to form Novo Nordisk A/S. Novo Nordisk’s early development was built on insulin research, manufacturing scale, and improvements in administration. It introduced human insulin, genetically engineered insulin made with yeast, and insulin-pen technology. The 1985 launch of NovoPen helped establish the company as both a pharmaceutical manufacturer and a developer of drug-delivery systems. Over time, the portfolio expanded beyond diabetes into human growth hormone, haemophilia and other bleeding disorders, hormone replacement therapy, and obesity treatment. The company’s most important recent growth engine has been the GLP-1 platform. Semaglutide is marketed for type 2 diabetes under the Ozempic and Rybelsus brands and for chronic weight management under Wegovy. These products transformed Novo Nordisk’s commercial profile, substantially increasing demand, manufacturing requirements, public visibility, and scrutiny over affordability, supply, promotion, and access. The company has responded with large-scale investments in active pharmaceutical ingredient production, fill-finish capacity, research, and commercial infrastructure, while also simplifying parts of its older insulin portfolio. Novo Nordisk is controlled by Novo Holdings A/S, the investment company wholly owned by the Novo Nordisk Foundation. The foundation-based ownership structure gives the company a long-term controlling shareholder and supports a corporate model commonly described through the Novo Nordisk Way. Novo Nordisk remains a publicly traded company, with B shares listed in Copenhagen and American Depositary Receipts listed in New York. Its strategic scope has broadened from diabetes care toward the stated ambition of defeating serious chronic diseases. Recent business development has included acquisitions and licensing in oral drug delivery, RNA therapeutics, cardiovascular disease, metabolic disease, rare blood disorders, manufacturing, and metabolic dysfunction-associated steatohepatitis. The acquisition of three former Catalent manufacturing sites expanded supply capacity, while the acquisition of Akero Therapeutics added the late-stage FGF21 analogue efruxifermin to the company’s MASH portfolio. As of 2026, Novo Nordisk is a large global healthcare organization with operations in dozens of countries, products marketed in roughly 170 markets, and a portfolio centered on metabolic and chronic disease. Its competitive position is shaped by scientific expertise, manufacturing scale, a major diabetes franchise, obesity medicines, and an extensive global commercial network. At the same time, it faces intense competition from Eli Lilly, pressure from changing reimbursement and pricing environments, possible loss of exclusivity for semaglutide in important markets, supply-chain demands, regulatory scrutiny, litigation, and the need to sustain innovation beyond its current GLP-1 franchise.
History
Novo Nordisk’s history begins with the arrival of insulin technology in Denmark in the early 1920s. Physiologist August Krogh and his wife Marie became interested in insulin after learning about the breakthrough in North America. August Krogh obtained permission to produce insulin in Denmark and, together with physician Hans Christian Hagedorn and industrialist August Kongsted, began developing extraction and purification methods. Their work led to the commercialization of insulin by Nordisk Insulinlaboratorium in 1923 and helped establish Denmark as an important center of diabetes research and manufacturing. Nordisk’s early activities were initially connected with Løvens Kemiske Fabrik before being organized as an independent company. The company developed manufacturing capabilities and created an associated foundation whose governance structure limited the founders’ ability to profit personally from insulin sales. This foundation-based ownership tradition ultimately became an important element of the modern Novo Nordisk structure. In 1925, brothers Harald and Thorvald Pedersen, who had previously worked at Nordisk, founded Novo Terapeutisk Laboratorium. Novo and Nordisk became direct competitors in insulin and related products. Both companies invested in research, production, clinical relationships, and international expansion. Nordisk developed expertise in insulin, growth hormone, and haemostasis, while Novo became known for insulin manufacturing, purification, and delivery systems. The companies’ product and technology development accelerated after the Second World War. Nordisk introduced human growth hormone therapy in the 1970s. Novo developed increasingly purified insulin and expanded its international operations. Human insulin produced through biotechnology became a major milestone: Novo began producing human insulin using genetically engineered yeast cells in the 1980s, helping replace animal-derived insulin with a product chemically identical to human insulin. The development of injection devices became another defining part of Novo’s identity. In 1985, Novo launched NovoPen, widely recognized as the first insulin pen device. The pen format made insulin administration more portable, discreet, and convenient than traditional vial-and-syringe use. Subsequent generations of pens and connected or reusable delivery systems reinforced the company’s combination of pharmaceutical research and device engineering. Novo and Nordisk merged in 1989 to form Novo Nordisk A/S. The merger created the world’s leading insulin producer and combined complementary scientific, manufacturing, and commercial capabilities. The new group was headquartered in Bagsværd and continued to expand internationally. In the early 1990s, certain non-core internal service activities were separated from the business. Novo Nordisk Engineering was demerged in 1991, and the company’s information-technology operations were later spun out as NNIT. In 2000, the enzymes business was separated into Novozymes, leaving Novo Nordisk focused primarily on healthcare. During the 1990s and 2000s, Novo Nordisk broadened its portfolio beyond traditional insulin. NovoSeven became an important treatment in haemophilia and other bleeding disorders. NovoRapid and other insulin analogues improved the timing and flexibility of mealtime insulin treatment. The company also developed oral diabetes medicines, growth hormone products, hormone therapies, and additional injection technologies. These products established a diversified specialist-pharmaceutical model built around chronic diseases requiring long-term treatment. The company entered obesity treatment more directly with liraglutide-based Saxenda, following the earlier development of Victoza for type 2 diabetes. The next major turning point was semaglutide. Ozempic was developed for type 2 diabetes, Rybelsus provided an oral semaglutide formulation, and Wegovy extended semaglutide into chronic weight management. The clinical and commercial success of these medicines reshaped Novo Nordisk’s scale and public profile, while also creating manufacturing shortages, pricing debates, lawsuits, regulatory scrutiny, and strong competition from Eli Lilly’s tirzepatide products. From 2020 onward, Novo Nordisk increased external innovation and portfolio expansion. It acquired or partnered with companies working in oral delivery, cardiovascular disease, RNA interference, rare blood disorders, metabolic disease, and MASH. Key transactions included Emisphere Technologies, Dicerna Pharmaceuticals, Forma Therapeutics, Inversago Pharma, Cardior Pharmaceuticals, and Akero Therapeutics. The company also acquired three manufacturing sites associated with Catalent through a transaction involving Novo Holdings, reflecting the strategic importance of production capacity for semaglutide and other high-demand therapies. The company’s growth produced broader economic and organizational consequences in Denmark. Rising demand for obesity medicines contributed to rapid sales and employment expansion, while the market value of Novo Nordisk became exceptionally large relative to Denmark’s economy. In response to the scale of expansion, management introduced leadership-development initiatives, expanded manufacturing, and redirected research toward serious chronic diseases beyond diabetes. In 2025, the company announced a substantial workforce reduction and appointed Maziar Mike Doustdar as CEO, signaling a more disciplined phase after years of rapid expansion. By 2026, Novo Nordisk remained a global healthcare leader focused on diabetes, obesity, cardiovascular disease, rare blood disorders, growth hormone, and related metabolic conditions. Its historical strengths are scientific specialization, biologics manufacturing, insulin and GLP-1 expertise, device innovation, and long-term foundation ownership. Its principal challenges are maintaining growth as competition increases, expanding access and affordability, managing patent and exclusivity pressures, meeting global supply requirements, and producing new medicines capable of extending the company’s leadership beyond semaglutide.
- 2026
Oral Wegovy treatment launches
[1]Novo Nordisk reports the launch of an oral semaglutide obesity treatment, extending its GLP-1 platform into a tablet format.
- 2025
Akero Therapeutics is acquired
[8]The acquisition adds efruxifermin, a late-stage treatment candidate for MASH.
- 2025
CEO transition and workforce restructuring
[2]Maziar Mike Doustdar becomes CEO, while the company announces a global reduction of approximately 9,000 positions.
- 2024
Cardior acquisition and Catalent manufacturing transaction
[7]Novo Nordisk adds an RNA-based cardiovascular platform and completes the acquisition of three former Catalent manufacturing sites.
- 2023
Inversago and Embark transactions announced
[9]The company adds metabolic-disease research and early-stage biotechnology capabilities.
- 2022
Forma Therapeutics acquisition agreed
[12]Novo Nordisk expands its rare blood-disorder portfolio with Forma Therapeutics.
- 2021
Dicerna acquisition announced
[12]The acquisition adds RNA interference technology and expands Novo Nordisk’s external innovation platform.
- 2020
Emisphere and Corvidia transactions announced
[12]Novo Nordisk expands its oral delivery and cardiovascular development capabilities through acquisitions.
- 2015
Saxenda launches in the United States
[16]Liraglutide-based Saxenda expands Novo Nordisk’s commercial presence from diabetes into chronic weight management.
- 2000
Novozymes is separated from Novo Nordisk
[15]The enzymes business is demerged as Novozymes, leaving Novo Nordisk as a focused healthcare company.
Products and positioning
Science-led global healthcare company focused on chronic disease, with particular strength in diabetes, obesity, protein-based medicines, GLP-1 therapies, and patient-friendly drug-delivery systems.
Type 2 diabetes medicine · 2017
Ozempic
Ozempic is Novo Nordisk’s once-weekly injectable semaglutide product for adults with type 2 diabetes. It belongs to the GLP-1 receptor agonist class and is used alongside diet and exercise under applicable regulatory indications. Ozempic became one of the company’s most commercially important products and a major source of public attention because semaglutide is pharmacologically related to the company’s obesity product Wegovy.
Chronic weight-management medicine · 2021
Wegovy
Wegovy is a higher-dose semaglutide product developed for chronic weight management in eligible adults and, in some markets, adolescents. It is administered by injection in established markets and forms the center of Novo Nordisk’s obesity franchise. Strong demand has driven major production investments, expanded commercial activity, affordability debates, and competition with Eli Lilly’s obesity medicines.
Oral type 2 diabetes medicine · 2019
Rybelsus
Rybelsus is an oral semaglutide medicine for type 2 diabetes. It provides a tablet-based alternative to injectable GLP-1 treatment and reflects Novo Nordisk’s effort to extend semaglutide across different routes of administration. The product also demonstrates the company’s strategic value in oral peptide delivery, an area supported by its acquisition of Emisphere Technologies.
Rapid-acting insulin analogue · 1999
NovoRapid
NovoRapid, marketed as NovoLog in the United States, is a rapid-acting insulin analogue used to help control blood glucose around meals and other times when rapid insulin action is needed. It is one of Novo Nordisk’s major modern insulin products and reflects the company’s historical expertise in recombinant insulin, formulation, and injection-device systems.
Long-acting basal insulin analogue · 2015
Tresiba
Tresiba is an ultra-long-acting basal insulin analogue designed to provide background insulin coverage over an extended period. It is used in diabetes treatment according to local approvals and has been positioned as a flexible basal-insulin option. Tresiba represents the continuation of Novo Nordisk’s core insulin franchise into newer-generation formulations.
Obesity medicine · 2014
Saxenda
Saxenda is a liraglutide-based medicine for chronic weight management. It preceded Wegovy in Novo Nordisk’s obesity portfolio and helped establish the company’s direct presence in the medical treatment of obesity. Although semaglutide products later became more prominent, Saxenda remains an important milestone in the development of Novo Nordisk’s obesity strategy.
Haemostasis and haemophilia medicine · 1996
NovoSeven
NovoSeven is a recombinant activated factor VII product used in the management of bleeding in selected patients, including people with haemophilia who develop inhibitors. Its development established Novo Nordisk as a significant supplier in haemostasis and rare blood disorders, areas that remain part of the company’s broader specialty-care portfolio.
Growth hormone therapy · 1999
Norditropin
Norditropin is Novo Nordisk’s somatropin growth hormone franchise. It is used for approved growth hormone deficiencies and related growth disorders, with delivery systems designed to support long-term treatment. The product line builds on Nordisk’s early leadership in human growth hormone and remains part of the company’s rare disease and endocrine portfolio.
Type 2 diabetes medicine · 2009
Victoza
Victoza is a once-daily liraglutide GLP-1 receptor agonist for type 2 diabetes. It was a major product in Novo Nordisk’s expansion into incretin-based therapies and provided the foundation for the later Saxenda obesity product. Victoza was also associated with historical disputes over promotion, side-effect disclosures, and product-liability claims.
Haemophilia medicine · 2024
Alhemo
Alhemo is the brand name for concizumab, a prophylactic treatment developed for selected patients with haemophilia A or B. It illustrates Novo Nordisk’s continuing investment in rare blood disorders and non-factor approaches to haemophilia management. Regulatory approvals and indications vary by jurisdiction.
Controversies
2026
False-advertising lawsuit against Eli Lilly
Novo Nordisk sued Eli Lilly in New Jersey, alleging that Lilly’s advertising for diabetes and obesity medicines was materially misleading because it allegedly misrepresented comparative clinical evidence. The dispute is unresolved and represents a major escalation in competition between the two GLP-1 manufacturers.
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania filed a lawsuit against Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several pharmacy benefit managers (PBMs), alleging that they colluded to raise insulin prices. The suit seeks structural changes, restitution, and financial penalties. The action names Novo Nordisk Inc. among the insulin manufacturers accused in the alleged price collusion.
2024
Pricing, access, and supply controversy surrounding GLP-1 medicines
The rapid demand for Ozempic and Wegovy intensified public and political criticism of US pricing, insurance coverage, shortages, unequal access, and the role of pharmaceutical distribution and pharmacy-benefit systems. Novo Nordisk responded with production expansion and access initiatives, while critics continued to challenge affordability.
2021
Novo Nordisk recalls certain product samples
Novo Nordisk voluntarily recalled 1,468 samples of Levemir, Tresiba, Fiasp, NovoLog and Xultophy to the consumer level because they had been stored below the required temperature. The recall affected product samples, not products broadly distributed to pharmacies or mail-order services; the company said it had received no reports of serious adverse events or injuries related to the recall.
2013
Danish transfer-pricing tax dispute
Novo Nordisk was required to repay approximately DKK 3.6 billion to Danish tax authorities in a transfer-pricing dispute. The case concerned the allocation of profits within the multinational group.
2013
Pancreatitis and pancreatic-cancer concerns involving incretin medicines
Scientists, regulators, and litigants debated whether incretin-class diabetes medicines, including Victoza, were associated with pancreatic side effects. Available evidence at the time did not establish the alleged causal relationship, but the issue generated product-liability litigation and regulatory attention.
2010
ABPI code breach involving Victoza
The Association of the British Pharmaceutical Industry found that Novo Nordisk breached its code of conduct by failing to provide adequate side-effect information for Victoza and promoting the product before market authorization.
Marketing campaigns
- 2023Wegovy and obesity-awareness marketing
United States · Europe · Global launch markets
Novo Nordisk expanded consumer and professional communication around chronic weight management as Wegovy rolled out internationally. The campaign environment emphasized obesity as a chronic disease while increasing public awareness of semaglutide treatment.
Outcome. The campaign helped establish Wegovy as a major obesity brand but also intensified scrutiny over demand, pricing, medicalization, celebrity-driven interest, and comparative advertising.
- 2014Cities Changing Diabetes
Global · Urban markets
Cities Changing Diabetes addressed the urban and social determinants associated with rising type 2 diabetes prevalence. The program brought together municipalities, academic institutions, healthcare organizations, and community groups.
Outcome. The initiative expanded Novo Nordisk’s diabetes work from medicines into public-health partnerships and city-level prevention efforts.
- 2014Changing Diabetes in Children
Low- and middle-income countries
Changing Diabetes in Children provides support for children with type 1 diabetes in countries where diagnosis, insulin, monitoring, and clinical care may be difficult to obtain. The program works with local partners and healthcare systems.
Outcome. The program became one of the company’s principal access and social-impact initiatives, reaching tens of thousands of children according to company reporting.
- 2005Changing Diabetes
Global
Changing Diabetes became Novo Nordisk’s long-running public-health and corporate-purpose platform. It connected the company’s commercial identity with diabetes awareness, education, prevention, patient support, and policy engagement.
Outcome. The platform became a recognizable global expression of Novo Nordisk’s diabetes mission and was extended through initiatives such as Changing Diabetes in Children.
Brand decisions
2026
Launch oral Wegovy formulationProduct launchBackground
Novo Nordisk sought to extend semaglutide-based obesity treatment beyond injections and respond to patient demand for oral dosing.
Action taken
The company launched an oral Wegovy formulation in 2026 markets.
Aftermath
The launch expanded the semaglutide franchise and created a new competitive front in oral obesity medicines.
2026
File false-advertising lawsuit against Eli LillyOtherBackground
Novo Nordisk alleged that Eli Lilly’s comparative advertising for obesity and diabetes medicines misrepresented clinical evidence and omitted material information.
Action taken
Novo Nordisk filed a federal lawsuit in New Jersey seeking to challenge Lilly’s advertising practices.
Aftermath
The case intensified the commercial and legal rivalry between the two leading GLP-1 manufacturers; the allegations remain unresolved.
- Eli Lilly and Company — Lilly said it stood behind its advertising and would defend the lawsuit vigorously.
2025
Acquire Akero TherapeuticsM&ABackground
MASH is a serious metabolic liver disease closely linked with obesity and type 2 diabetes. Novo Nordisk sought a late-stage asset that could extend its metabolic-disease portfolio.
Action taken
Novo Nordisk agreed to acquire Akero Therapeutics and its FGF21 analogue efruxifermin.
Aftermath
The acquisition added a phase 3 MASH asset and expanded Novo Nordisk’s ambitions in metabolic and liver disease.
Cash consideration and contingent value right. USD 4.7 billion at closing plus a potential USD 0.5 billion contingent value right (October 2025 announcement)
2025
Global workforce restructuringStrategyBackground
Novo Nordisk faced heightened competition in obesity medicines, changing market expectations, and the need to improve organizational efficiency after rapid expansion.
Action taken
The company announced a reduction of approximately 9,000 positions globally and planned to redirect savings toward diabetes and obesity opportunities.
Aftermath
The restructuring marked a shift from rapid capacity and headcount expansion toward sharper execution, cost discipline, and portfolio prioritization.
Expected annualized savings. Approximately DKK 8 billion from 2026 onward (2025 announcement)
2024
Acquire three manufacturing sites associated with CatalentM&ABackground
Rapid demand for semaglutide medicines created a need for additional fill-finish and manufacturing capacity.
Action taken
Novo Nordisk acquired three manufacturing sites from Novo Holdings after Novo Holdings completed its acquisition of Catalent.
Aftermath
The sites expanded capacity and supply-chain flexibility while preserving production commitments to existing customers.
Acquisition price for three sites. Approximately USD 11.7 billion (2024 completion)
2024
Acquire Cardior PharmaceuticalsM&ABackground
Novo Nordisk aimed to establish a stronger cardiovascular-disease presence using Cardior’s RNA-based therapeutic approach.
Action taken
The company agreed to acquire Cardior and its lead compound CDR132L, then in phase 2 development for heart failure.
Aftermath
The deal broadened Novo Nordisk’s cardiovascular pipeline and linked its metabolic-disease expertise with a cardiac RNA platform.
Maximum transaction value. Up to approximately EUR 1.025 billion (March 2024 announcement)
2023
Acquire Inversago PharmaM&ABackground
Novo Nordisk wanted to strengthen its pipeline in obesity and related metabolic disorders with an oral CB1 inverse agonist.
Action taken
The company agreed to acquire Inversago Pharma and its lead asset INV-202.
Aftermath
The transaction added a non-GLP-1 metabolic research approach to the obesity pipeline.
Acquisition value. Up to approximately USD 1 billion (August 2023 announcement)
2022
Acquire Forma TherapeuticsM&ABackground
Novo Nordisk sought to strengthen its rare blood-disorder portfolio, including treatments for sickle-cell disease.
Action taken
The company agreed to acquire Forma Therapeutics.
Aftermath
The acquisition expanded Novo Nordisk’s rare-disease pipeline and complemented its haemophilia and haemostasis businesses.
Acquisition value. Approximately USD 1.1 billion (September 2022 announcement)
2021
Acquire Dicerna PharmaceuticalsM&ABackground
Novo Nordisk aimed to expand its research platform through RNA interference technology and Dicerna’s development programs.
Action taken
Novo Nordisk agreed to acquire Dicerna Pharmaceuticals.
Aftermath
The deal added RNAi capabilities and broadened Novo Nordisk’s external innovation base beyond its traditional protein and peptide platforms.
Acquisition value. Approximately USD 3.3 billion (November 2021 announcement)
2020
Acquire Emisphere TechnologiesM&ABackground
Novo Nordisk sought technology for oral delivery of peptide and protein medicines, an important challenge for expanding beyond injections.
Action taken
The company acquired Emisphere and its Eligen oral-delivery technology.
Aftermath
The transaction supported Novo Nordisk’s oral semaglutide ambitions and strengthened the technological basis for tablet-based peptide medicines.
Acquisition consideration. Approximately USD 1.35 billion (2020 announcement and transaction)
Showing the 10 most recent.
Recent events
- Unconfirmed
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion[21]
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
- Unconfirmed
Novo Nordisk reports new CagriSema study data on reduced food noise and organ and bone health improvements[24]
Reported:
Novo Nordisk released new data this week from a yearlong functional magnetic resonance imaging study showing that CagriSema, its combination of cagrilintide and semaglutide, reduced food noise (persistent thoughts about food) and showed improvements to organ and bone health in people with obesity or who were overweight. Novo said CagriSema changed how the brain reacted to tempting, high-calorie foods in areas linked to cravings, pleasure and self-control.
- Unconfirmed
Novo Nordisk to pay up to $2.6 billion to Hengrui for rights to weight-loss pill[25]
Reported:
Reuters reported that Novo Nordisk is to pay up to $2.6 billion to China's Hengrui Pharma for rights to a weight-loss pill.
- Unconfirmed
Novo Nordisk enters €1.17 billion deal with Nanexa for injection technology[26]
Reported:
Novo Nordisk entered a €1.17 billion deal with Nanexa covering injection technology, and Nanexa's shares soared on the news.
- Unconfirmed
Novo Nordisk strikes licensing deal with a Swedish company[27]
Reported:
MarketWatch reported that Novo Nordisk has struck a licensing deal with a Swedish company, and that news of the deal sent the Swedish company's stock soaring. The report notes the deal came after Novo's capital-markets day was received poorly. The Swedish counterparty is not named in the available source text, and no deal date is stated in the headline.
Nanexa signs $1.33 billion global licensing deal with Novo Nordisk for PharmaShell technology[28]
Reported:
Swedish drug-delivery company Nanexa announced a global licensing agreement with Novo Nordisk, granting the maker of Wegovy and Ozempic exclusive rights for up to five development programs to use Nanexa's PharmaShell technology, an ultra-thin inorganic coating on drug particles that controls release over time, for long-acting injectable drugs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Nanexa is eligible for an upfront payment of around $700 million, milestone payments for development and regulatory achievements, and low single-digit royalties on future product sales, in a deal reported at $1.33 billion. Nanexa shares surged more than 150% at Friday's open in Stockholm before paring gains.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
- Unconfirmed
Novo Nordisk CEO says company open to direct NYSE share listing[29]
Reported:
Novo Nordisk's chief executive said the company is open to a direct listing of its shares on the New York Stock Exchange.
Novo Nordisk lays out growth strategy and pipeline targets at Capital Markets Day[30]
Reported:
At its Capital Markets Day on Monday, Novo Nordisk laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, promising a pipeline of potential blockbuster products and diversification beyond obesity and diabetes. Targets included launching more than five potential multi-blockbuster drugs by 2030, more than 150 billion Danish kroner (about $23 billion) in pipeline sales by 2035, at least five Phase 3 programs in obesity and diabetes plus five across other therapeutic areas, and a tenfold increase in patients on its GLP-1 drugs by 2030. Investors sold off Novo's stock after the presentation, with growth targets matching industry averages rather than outpacing them.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Novo Nordisk launches once-daily Wegovy weight-loss pill in the US[31]
Reported:
Novo Nordisk launched the once-daily pill version of its weight-loss drug Wegovy in the United States on Monday, following FDA approval in December 2025. The pill is priced at $199-$299 per month and will be sold through US pharmacies including Costco and CVS and telehealth providers such as Ro, LifeMD, WeightWatchers, GoodRx and NovoCare Pharmacy.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Novo Nordisk launches oral semaglutide in India[32]
Reported:
Novo Nordisk announced the launch of oral semaglutide in India for the treatment of type 2 diabetes. The source says the pill had been approved by India’s Drugs Controller General in 2020.
Showing the 10 most recent.
Sources42 sources
- 1Our heritagenovonordisk.com
- 22025 at a glanceannualreport.novonordisk.com
- 3Financial performance, Annual Report 2025annualreport.novonordisk.com
- 4Our productsnovonordisk.com
- 5Executive Managementnovonordisk.com
- 6Novo Nordisk Annual Report 2025novonordisk.com
- 7Catalent manufacturing sites acquisition completednovonordisk.com
- 8Akero Therapeutics acquisition announcementnovonordisk.com
- 9Inversago Pharma acquisition announcementnovonordisk.com
- 10Novo Nordisk Form 20-F 2019novonordisk.com
- 11Novo Nordisk Annual Report 2013novonordisk.com
- 12Novo Nordisk Q4 2025 Investor Presentationnovonordisk.com
- 13Novo Nordisk Annual Report 2024annualreport.novonordisk.com
- 14Novo Nordisk sues Eli Lilly over alleged deceptive advertisingaxios.com
- 15NovoSeven is launchednovonordisk.com
- 16Saxenda launches in the United Statesnovonordisk.com
- 17Wegovy and obesity-awareness marketingannualreport.novonordisk.com
- 18Discontinue inflammatory-disorder researchen.wikipedia.org
- 19Acquisition price for three sitesannualreport.novonordisk.com
- 20Acquire Cardior Pharmaceuticalsnovonordisk.com
- 21Pennsylvania sues insulin makers and PBMs over alleged insulin price collusionncpa.org
- 22Pennsylvania sues insulin makers and PBMs over alleged insulin price collusionklvi.iheart.com
- 23Novo Nordisk recalls certain product samplesprnewswire.com
- 24诺和诺德公布CagriSema新研究数据：减少食物噪音并改善器官与骨骼健康cnbc.com
- 25诺和诺德将向恒瑞支付至多26亿美元获得减肥药权益news.google.com
- 26诺和诺德与Nanexa达成11.7亿欧元注射技术交易news.google.com
- 27诺和诺德与一家瑞典公司达成授权合作news.google.com
- 28Nanexa与诺和诺德签署13.3亿美元PharmaShell技术全球授权协议cnbc.com
- 29诺和诺德CEO称公司对直接在纽约证券交易所上市持开放态度news.google.com
- 30诺和诺德在资本市场日公布增长战略与管线目标cnbc.com
- 31诺和诺德在美国推出每日一次Wegovy减肥药片wsbtv.com
- 32诺和诺德在印度推出口服司美格鲁肽economictimes.indiatimes.com
- 33诺和诺德与乐城管理局签署战略合作备忘录prnasia.com
- 34诺和诺德任命罗马尼亚企业事务总监zfenglish.com
- 35诺和诺德上调2020年销售额及营业利润展望finance.yahoo.com
- 36宣布诺和诺德收购 Corvidia Therapeuticsfinanznachrichten.de
- 37FDA 批准 Fiasp 用于 2 岁及以上儿童ajmc.com
- 38Novo Nordisk任命Vikrant Shrotriya领导印度业务health.economictimes.indiatimes.com
- 39Dicerna与诺和诺德就肝脏相关疾病开展合作biospace.com
- 40Novo Nordisk A/S: Novo Nordisk raises sales and operating profit outlook for 2021finanznachrichten.de
- 41Novo Nordisk launches once-daily Wegovy weight-loss pill in the US; cost ranges from $199-$299 a month | Company Business Newslivemint.com
- 42Novo Nordisk Recalls Insulin Product Samples in USmedscape.com
Cite this profile: Cite the canonical profile. /brand-wiki/novo-nordisk · Editorial policy · How profiles are compiled